GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NexImmune Inc (NAS:NEXI) » Definitions » Cash Flow from Investing

NexImmune (NexImmune) Cash Flow from Investing : $-0.05 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NexImmune Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, NexImmune spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, NexImmune gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


NexImmune Cash Flow from Investing Historical Data

The historical data trend for NexImmune's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexImmune Cash Flow from Investing Chart

NexImmune Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial 9.42 0.22 -53.81 50.32 -0.04

NexImmune Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 -0.04 -0.01 - -

NexImmune Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

NexImmune's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

NexImmune's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NexImmune  (NAS:NEXI) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

NexImmune's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means NexImmune spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

NexImmune's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means NexImmune gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

NexImmune's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means NexImmune spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

NexImmune's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means NexImmune gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

NexImmune's purchase of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means NexImmune spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

NexImmune's sale of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means NexImmune gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

NexImmune's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means NexImmune paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

NexImmune's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means NexImmune paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

NexImmune's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means NexImmune paid $0.00 Mil for other investing activities.


NexImmune Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of NexImmune's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


NexImmune (NexImmune) Business Description

Traded in Other Exchanges
N/A
Address
9119 Gaither Road, Gaithersburg, MD, USA, 20877
NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
Executives
Alan S. Roemer director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Timothy Stover officer: VP, Corporate Controller C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Zhengbin Yao director 10301 STELLA LINK ROAD, HOUSTON TX 77025
Leena Gandhi director C/O NEXIMMUNE, 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Timothy Bertram director C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Paul D'angio director C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Grant Verstandig director C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Mathias Oelke officer: Chief Science Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Kristi Jones officer: Chief Operating Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Jerome B Zeldis officer: EVP of R&D 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Scott Carmer director, officer: President and CEO C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
John Trainer officer: Chief Financial Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Robert Douglas Knight officer: Chief Medical Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877